Sutherland Global Services
Sutherland Global Services Sutherland Global Services Sutherland Global Services

“It's far more important to know what person the disease has than what disease the person has.”
- Hippocrates, the father of modern medicine

The evolving field of Precision Medicine is currently seen as a knight in shining armor that can significantly contribute to the efforts to achieve better quality healthcare delivery. 

Precision medicine challenges the “one size fits all” approach, in which a standard dose is given to a patient with a particular disease and symptoms. This can lead to serious adverse effects and increased health cost, along with lowering the success rate of treating the disease. Precision medicine lays greater emphasis on the fact that each individual is biologically unique, and thereby takes in account individual variability in genes, environment, and lifestyle in a patient’s treatment.

Precision medicine is witnessing increased engagement from various stakeholders

Precision medicine, also known as personalized healthcare, has witnessed initial success, especially in cancer treatment. For example, between 1999 and 2014, deaths due to pediatric cancer were down by ~20%.

Though it may take time, even years, for precision medicine to achieve mass penetration; it is gaining acceptability among all the concerned stakeholders – right from healthcare professionals to the White House.

The US government has made several investments and formed partnerships through its various machineries including the National Institutes of Health, Department of Veterans Affairs, and Food and Drug Administration for the development of precision medicine, and thereby making health care more effective.

Precision medicine got its biggest push from the US President Barack Obama with the launch of Precision Medicine Initiative (PMI) in 2015. Under the PMI, $215 million was allotted for FY 2016 to build a large-scale research participant group and increase efforts in cancer genomics. Additionally, $55 million has been allotted to create a public database of health information of about million volunteers under the Precision Medicine Cohort program.  

Healthcare providers have also initiated the process to change policies needed to adopt precision medicine. Although some of the providers are playing the waiting game, adoption will surely increase, as more and more success stories starring precision medicine are reported.

A huge amount of money is diverted for the development of precision medicine, which shows the growing interest of private equity and venture capitalists in the field of precision medicine.


Company Company Specialization Amount Raised($m) P/E
Develops medical products for life-science innovators 225.0 TPG Growth, venBio, Fidelity Biosciences, Amgen Ventures, Baxter Ventures, Osage University Partners and the Longevity Fund
Develops platforms and informatics for biomarker discoveries, diagnostic tests and breakthrough in precision medicine


80.0 Essex Woodlands
Develops precision medicine software platform 39.6> Ascension Ventures, Safeguard Scientifics and Social Capital Partners
Develops precision cardiovascular therapies 26.0 Apple Tree and Sofinnova Partners
Develops sequencing data from gene panels, exomes, whole genomes and transcriptomes 24.0 Sequoia Capital and Papillon Capital
Develops an online portal that provides genomic testing data 15.0 Apple Tree Partners
Develops precision medicine for cancer treatment 8.6 Ackermans and van Haaren


The intensification of precision medicine can transform the way both doctors and pharma companies approach patient treatment. With growing acceptance of precision medicine, stakeholders in the healthcare system need to be better equipped, because the wave of precision medicine can hit them much sooner than expected.


Nikhil Loharuka, Senior Director – Financial Research
Financial Research
Leave a comment
This Blog is awesome it is well described and step by step. Keep updating new blogs.
Posted on 5/22/17 6:01 PM.
Explore by Category
Financial Research

Strategy & Business Research
Popular Blogs
Fintech! Cost reaper or White collar multiplier?

Testimonials View All

"Thank you very much for compiling this summary - it is a fantastic overview and saves us a lot of time. I particularly liked the quotes that you pulled from the transcripts; they were exactly what we were looking for."

Analyst, Canada-based Investment Bank

"Your model building and reconstruction is remarkable for its accuracy and speed, and you saved me several weeks of work, which I greatly appreciate."

Star Analyst, US-based Investment Bank

"Sutherland's analyst is diligent, accurate, technical and thoughtful with all of his work. He is a very thorough researcher and can find difficult statistics. He stays on top of long term projects and will continue to try to complete if unsuccessful. He continues to be a huge asset to our team."

Senior Banker, Mid-Market Investment Bank

"Sutherland's analyst is an invaluable resource to me and my team. We can count on him to generate thorough, accurate materials quickly. I am impressed with Sutherland's analysts' ability to perfectly capture what it is we were looking for, having only received limited instructions via email."

Senior Banker, Large Investment Bank

"I would like to mention that we had a really good week with 4 out of 8 meetings already reaching the "hot" category. Great progression with the type and kind of companies we are meeting with."
Keep up the hard work.

Business Development Manager, A Global Business and Financial Centre based out of the GCC

"This is a small note to say that it has been great working with you. Projects have been:
1- Delivered on time.
2- Delivered to top standards.
3- Not once there has been a delay (if there has been it has been discussed prior)
4- You have also gone beyond work hours in accommodating our special requests from time to time.
5- Particularly want to mention Fruit Trees study where your role was very key and well positioned in dealing with our "end client". This was truly outstanding.
Full marks.
We value this partnership and you have treated it beyond a client/supplier relationship.
Please keep up the good work.

Director, A leading Consulting Group in the Middle East and Africa

We have never had many policies in the database, and until recently our process was to reach out to advisors for that plan. Our Michigan team had precious few medical policies as well. I wanted to call out the Sutherland team for their amazing work in adding over a hundred new policies-not just PA forms, but fully-developed medical policies as well. Many of these were dated 2016 and earlier, so they had been missed for years.
Our Mumbai team is struggling with our conventions, working all day with Excel, and large workloads. Every plan they've pulled this month has been brand-new to them. These are plans we've researched multiple times this year alone, and they still manage to dig up all kinds of new information. This is not something we gather statistics on, but anecdotally, I've been reading a lot of new (previously-missed) policies in the last two weeks.
I'm very glad to have this kind of ingenuity on our side, enhancing our product a few plans at a time. If you've had a similar experience, I ask you to please give the Mumbai team that feedback as well.

Project Manager, A leading global health insights provider

Terms of Service   |    Site Map
© 2013 - 2019 Sutherland Insights. All Rights Reserved
Share Us @